Type 1 Diabetes

NIAID is committed to advancing the understanding of autoimmune diseases such as type 1 diabetes and to conducting clinical studies to develop effective prevention and treatment strategies. The following are selected studies supported by NIAID and recruiting people with type 1 diabetes or their relatives. The links lead to full study titles, descriptions, site locations and contact information.

Tocilizumab (TCZ) in New-onset Type 1 Diabetes (EXTEND) (NCT02293837)
EXTEND is a clinical research study that will test whether a therapy called tocilizumab can stop the immune system from attacking the remaining beta cells and possibly extend the ability to naturally produce insulin in individuals recently diagnosed with type 1 diabetes. Individuals 6 to 45 years old who were diagnosed with type 1 diabetes mellitus (T1DM), using the American Diabetes Association T1DM criteria, within 100 days of study enrollment may be eligible to volunteer.

Pathway to Prevention Study (NCT00097292)
The goal of this study is to enhance the understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes. Individuals 1 to 45 years old who have an immediate family member with type 1 diabetes (such as a child, parent, or sibling) or individuals 1 to 20 years old who have an extended family member with type 1 diabetes (such as a cousin, niece, nephew aunt, uncle, grandparent, or half-sibling) may be eligible to volunteer.

Teplizumab for Prevention of Type 1 Diabetes In Relatives “At-Risk” (NCT01030861)
This study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes in relatives determined to be at very high risk for developing the disease. Individuals who have relatives with type 1 diabetes and presence of at least two confirmed diabetes autoantibodies may be eligible to volunteer.

Content last reviewed on March 7, 2017